A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
A phase 2 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., now recruiting.
Overview
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec is a phase 2 interventional study registered as NCT07332000 by Candel Therapeutics, Inc., with 45 participants planned, started 2025-10-30 and due to reach its primary completion in 2027-02. Interventions recorded: aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT). Conditions listed: Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
- TrialRandomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Shares Aglatimagene besadenovec, Candel Therapeutics, Prostate cancer.
- TrialAglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
- TrialCAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC